• EPA-Insight

Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitor

In 2019 Targovax reported encouraging data from part 1 of a trial in PD-1 checkpoint refractory melanoma. This trial examines how ONCOS-102 reactivates the immune system of patients that have progressed on checkpoint inhibitor treatment. The aim is to trigger relevant T-cell production and infiltration into the tumor so that patients who have become refractory can benefit from retreatment with the checkpoint inhibitor. Data from part 2 of this trial is expected later in 2020.

For more on this story.....

9 views0 comments

© 2019 by EPA-Insight

Follow Us

  • Grey Facebook Icon
  • Grey Twitter Icon
  • Grey LinkedIn Icon
  • Grey YouTube Icon